title: Novel links among peroxiredoxins, endothelial dysfunction, and severity of atherosclerosis in type 2 diabetic patients with peripheral atherosclerotic disease.
abstract: Peroxiredoxins, a group of antioxidant protein enzymes (PRDX1 to 6), are reported as antiatherogenic factors in animals; however, human studies are lacking. The present work aims to provide baseline data regarding the phenotype of PRDX1, 2, 4, and 6 in diabetic patients with peripheral atherosclerosis disease (PAD) and their relation to endothelial dysfunction (ED) and disease severity. Plasma levels of PRDX1, 2, 4, and 6 and markers of endothelial dysfunction (ICAM-1 and VCAM-1) were measured using ELISA in 55 type 2 diabetic patients having PAD and 25 healthy subjects. Ankle-brachial index (ABI), body mass index (BMI), triglycerides (TG), total cholesterol, HbA1c, and insulin resistance (HOMA IR) were measured. PRDX1, 2, 4, and 6 levels were significantly higher in patients compared to controls (PRDX1 21.9 ± 5.71 vs 16.8 ± 3.9 ng/ml, P < 0.001, PRDX2 36.5 ± 14.83 vs 20.4 ± 8.61 ng/ml, P < 0.001, PRDX4 3,840 ± 1,440 vs 2,696 ± 1,972 pg/ml, P < 0.005, PRDX6 311 ± 110 vs 287.9 ± 114 pg/ml, P < 0.05). PRDX1 and PRDX4 correlated negatively with ABI (r = -0.273, P < 0.05 and r = -0.28, P < 0.05, respectively), while PRDX1 and PRDX2 correlated positively with HOMA/IR and TG (r = 0.276, P < 0.01 and r = 0.295, P < 0.01, respectively). ICAM-1 was associated with PRDX2 and log PRDX6 (r = 0.345, P = 0.0037 and r = 0.344, P = 0.0038). Our results provide strong links among PRDXs, ED, and severity of PAD in diabetic patients which warrants further evaluation to clarify whether high circulating levels of PRDXs are a consequence of chronic atherosclerotic disease or a predisposing factor for later cardiovascular events.
authors.affiliation: Physiology Department, Medical College and King Khalid University Hospital, King Saud University, P.O. BOX 2925(29), Riyadh, 11464, Saudi Arabia, emaneleter@yahoo.com.
authors.forename: Eman
authors.initials: E
authors.lastname: El Eter
authors.forename: Abeer
authors.initials: A
authors.lastname: Al Masri
authors.forename: Shahid
authors.initials: S
authors.lastname: Habib
authors.forename: Hana
authors.initials: H
authors.lastname: Al Zamil
authors.forename: Ahmed
authors.initials: A
authors.lastname: Al Hersi
authors.forename: Fawaz
authors.initials: F
authors.lastname: Al Hussein
authors.forename: Mohamed
authors.initials: M
authors.lastname: Al Omran
mesh_terms: D055109:Ankle Brachial Index; D050197:Atherosclerosis / Q000097:blood / Q000150:complications / Q000473:pathology / Q000503:physiopathology*; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000473:pathology / Q000503:physiopathology*; D004730:Endothelium, Vascular / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000097:blood* / Q000150:complications / Q000473:pathology / Q000503:physiopathology*; D054464:Peroxiredoxins / Q000097:blood*
chemical_list: D015415:Biomarkers; D054464:Peroxiredoxins